An integrated microfluidic electrochemiluminescence device for point-of-care testing of acute myocardial infarction

Heart-type fatty acid binding protein (H-FABP) is an early biomarker for acute myocardial infarction. The concentration of H-FABP in circulation sharply increases during myocardial injury. Therefore, fast and accurate detection of H-FABP is of vital significance. In this study, we developed an electrochemiluminescence device integrated with microfluidic chip (designed as m-ECL device) for on-site detection of H-FABP. The m-ECL device is consisted of a microfluidic chip that enable easy liquid handling as well as an integrated electronic system for voltage supply and photon detection. A sandwich-type ECL immunoassay strategy was employed for H-FABP detection by using Ru (bpy)32+ loaded mesoporous silica nanoparticles as ECL probes. This device can directly detect H-FABP in human serum without any pre-treatment, with a wide linear range of 1-100 ng/mL and a low limit of detection of 0.72 ng/mL. The clinical usability of this device was evaluated using clinical serum samples from patients. The results obtained from m-ECL device are well matched with those obtained from ELISA assays. We believe this m-ECL device has extensive application prospects for point-of-care testing of acute myocardial infarction.

Automated summary

Heart-type fatty acid binding protein (H-FABP) is an early biomarker for acute myocardial infarction. Researchers developed an electrochemiluminescence device integrated with a microfluidic chip (m-ECL device) for on-site detection of H-FABP. The device enables direct detection of H-FABP in human serum without any pre-treatment and shows promising application prospects for point-of-care testing of acute myocardial infarction.